This article was originally published on TipRanks.com Exact Sciences Corp.
Exact Sciences (EXAS) is an American cancer screening and diagnostics company. Its products include colorectal cancer test Cologuard and Oncotype DX, which helps …
Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings.
Exact Sciences provided preliminary guidance for its fourth quarter performance as per which, the company expects to exceed consensus revenue estimates. In an …
Exact Sciences (EXAS) has pre-announced first quarter results, with total revenue up 114% year-over-year at $348 million, surpassing the Street estimate of $342.6 …
Exact Sciences Corporation’s (EXAS) preliminary quarterly results blew expectations out of the water. Yesterday, the molecular diagnostics company released preliminary results for its …
One area of the market that has been gaining steam: biotech stocks. A flurry of deals, FDA approvals, and recent innovations in the …
Shares of molecular diagnostics company Exact Sciences (NASDAQ:EXAS) rose by double digits today on heavy volume, thanks to a new U.S.
Rick Wise: High surgeon intrigue in TRXC’s Senhance; Mark Massaro: EXAS could hit 2.7M in tests by 2021.
Pacira’s Exparel “Hit Where It Needed to Most” Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were falling 12% yesterday after the drug maker’s pain medicine …
